Evidence map›Paper›PMID 36066188›Full record

ReviewBiochemical Society transactions2022

Sometimes less is more: inhibitory infrared light during early reperfusion calms hyperactive mitochondria and suppresses reperfusion injury.

Paul T Morse, Junmei Wan, Jamie Bell, Icksoo Lee, Dennis J Goebel, Moh H Malek, Thomas H Sanderson, Maik Hüttemann

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical Society transactions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Cardiac Tyrosine 97 Phosphorylation of CytochromeInternational journal of molecular sciences · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Paul T MorseCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, U.S.A.
Junmei WanCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, U.S.A.
Jamie BellCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, U.S.A.
Icksoo LeeCollege of Medicine, Dankook University, Cheonan-si, Chungcheongnam-do 31116, Republic of Korea.
Dennis J GoebelDepartment of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI 48201, U.S.A.
Moh H MalekDepartment of Health Care Sciences, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, Detroit, MI 48201, U.S.A.
Thomas H SandersonDepartment of Emergency Medicine, University of Michigan Medical School, Ann Arbor, MI 8109, U.S.A.
Maik HüttemannCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, U.S.A.ORCID 0000-0001-6310-7081
Wayne State University · USDankook University · KREugene Applebaum College of Pharmacy and Health Sciences · USUniversity of Michigan · US

Funding

Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac ArrestU44NS125160 · NINDS · MITOVATION, INC. · PI MAIK HUETTEMANN, Thomas Hudson Sanderson · 2022 to 2026
$3.6M
Non-invasive mitochondrial modulation therapy for ischemic strokeR01NS120322 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUETTEMANN, MAIK, SANDERSON, THOMAS HUDSON · 2021 to 2025
$2.3M
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain InjuryR42NS105238 · NINDS · MITOVATION, INC. · PI HUETTEMANN, MAIK, SANDERSON, THOMAS HUDSON · 2018 to 2020
$1.8M
Control of Cell Respiration and Apoptosis by Phosphorylation of Cytochrome cR01GM116807 · NIGMS · WAYNE STATE UNIVERSITY · PI HUETTEMANN, MAIK · 2017 to 2020
$1.5M
NIGMS NIH HHS R01 GM116807NINDS NIH HHS R01 NS120322NINDS NIH HHS R42 NS105238NINDS NIH HHS U44 NS125160
6 · The paper itself

Abstract

Ischemic stroke affects over 77 million people annually around the globe. Due to the blockage of a blood vessel caused by a stroke, brain tissue becomes ischemic. While prompt restoration of blood flow is necessary to save brain tissue, it also causes reperfusion injury. Mitochondria play a crucial role in early ischemia-reperfusion injury due to the generation of reactive oxygen species (ROS). During ischemia, mitochondria sense energy depletion and futilely attempt to up-regulate energy production. When reperfusion occurs, mitochondria become hyperactive and produce large amounts of ROS which damages neuronal tissue. This ROS burst damages mitochondria and the cell, which results in an eventual decrease in mitochondrial activity and pushes the fate of the cell toward death. This review covers the relationship between the mitochondrial membrane potential (ΔΨm) and ROS production. We also discuss physiological mechanisms that couple mitochondrial energy production to cellular energy demand, focusing on serine 47 dephosphorylation of cytochrome c (Cytc) in the brain during ischemia, which contributes to ischemia-reperfusion injury. Finally, we discuss the use of near infrared light (IRL) to treat stroke. IRL can both stimulate or inhibit mitochondrial activity depending on the wavelength. We emphasize that the use of the correct wavelength is crucial for outcome: inhibitory IRL, applied early during reperfusion, can prevent the ROS burst from occurring, thus preserving neurological tissue.

Indexed as

Reperfusion InjuryStrokeHumansIschemiaMitochondriaReactive Oxygen SpeciesReperfusionReactive Oxygen Speciescomplex IVcytochrome celectron transport chaininfrared lightmitochondriareactive oxygen species

Identifiers

PMID36066188
PMCPMC10121102
OpenAlexW4294763640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.